Meta analysis: Hydroxychloroquine studies from North America '3.7 times more likely to report negative results than studies from rest of world combined'

A real-time meta analysis of 238 studies of early hydroxychloroquine treatment for COVID-19 found "evidence of bias towards publishing negative results" and reveals that "studies from North America are 3.7 times more likely to report negative results than studies from the rest of the world combined."

Results show 100% of early treatment studies reporting positive effect, with an estimated reduction of 65% in the effect measured (death, hospitalization, etc.).

Late treatment studies are mixed, with 72% showing positive effects, and an estimated reduction of 22% in the random effects meta-analysis. "Negative studies mostly fall into the following categories: they show evidence of significant unadjusted confounding, including confounding by indication; usage is extremely late; or they use an excessively high dosage."

Zelenko Protocol discoverer Dr. Vladimir Zelenko told America's Frontline Doctors that "65% improvement with early treatment is an underestimate.  If you remove the studies that did not use zinc and an antibiotic, the remaining studies would show a greater then 85% benefit."

Dr. Zelenko further stated: "There has been a coordinated effort to commit academic fraud to build a false narrative. The wealthier countries are more prone to false propaganda because they can afford to bow down to false gods."

‍